Cheng I Wang PhD
Biotechnology, Pharmacy and Medicine
Singapore, Singapore, Singapore
Connect with the speaker?
Dr. Cheng-I Wang joined SIgN in 2009 as head of the human monoclonal antibody technology platform, focusing on the discovery and development of human antibodies against infection and immune disorders. Prior to joining SIgN, Dr. Wang had worked in the field of drug discovery for a number of biotechnology and pharmaceutical companies in the US.
His research has been focusing on designing novel functions into protein and antibody molecules using a combination of structure-based rational design and combinatorial approaches. Dr. Wang received his Ph.D. in Chemistry from Washington University and postdoctoral training in the Department of Pharmaceutical Chemistry at the University of California, San Francisco.
His research has been focusing on designing novel functions into protein and antibody molecules using a combination of structure-based rational design and combinatorial approaches. Dr. Wang received his Ph.D. in Chemistry from Washington University and postdoctoral training in the Department of Pharmaceutical Chemistry at the University of California, San Francisco.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)
Quick Links
- 50 Division Street, Suite 501,
- Somerville, NJ 08876
- support@emedevents.com